{
    "nct_id": "NCT04580485",
    "official_title": "A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors",
    "inclusion_criteria": "* Ability to comprehend and willingness to sign an ICF.\n* Willing and able to conform to and comply with all Protocol requirements.\n* Histologically or cytologically confirmed advanced/metastatic SCCHN, NSCLC, ovarian cancer, TNBC, CRPC, bladder cancer, and specified GI malignancies (defined as CRC, gastric/GEJ cancer, HCC, PDAC, or SCAC) that progressed after treatment with available therapies (including anti PD-(L)1 therapy (if applicable).\n* Willingness to undergo pre- and on-treatment tumor biopsy.\n* Have CD8 T-cell-positive tumors.\n* Presence of measurable disease according to RECIST v1.1.\n* ECOG performance status 0 to 1.\n* Life expectancy > 12 weeks.\n* Willingness to avoid pregnancy or fathering children based.\n* Acceptable laboratory parameters\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Clinically significant cardiac disease.\n* Known or active CNS metastases and/or carcinomatous meningitis.\n* Active or inactive autoimmune disease or syndrome that required systemic treatment in the past 2 years or receiving systemic therapy for an autoimmune or inflammatory disease..\n* Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (doses > 10 mg daily of prednisone or equivalent) or any other form of immunosuppressive therapy within 7 days before the first dose of study treatment.\n* Known additional malignancy that is progressing or requires active treatment,or history of other malignancy within 2 years of the first dose of study treatment.\n* Has not recovered to â‰¤ Grade 1 from toxic effects of prior therapy and/or complications from prior surgical intervention before starting study treatment.\n* Evidence of interstitial lung disease, history of interstitial lung disease, or active, noninfectious pneumonitis.\n* Immune-related toxicity during prior immune therapy for which permanent discontinuation of therapy is recommended, or any immune-related toxicity requiring intensive or prolonged immunosuppression to manage.\n* Any prior chemotherapy, biological therapy, or targeted therapy to treat the participant's disease within 5 half-lives or 28 days (whichever is shorter) before the first dose of study treatment.\n* Any prior radiation therapy within 28 days before the first dose of study treatment.\n* Undergoing treatment with another investigational medication or having been treated with an investigational medication within 5 half-lives or 28 days (whichever is shorter) before the first dose of study treatment.\n* Concomitant treatment with strong CYP3A4 inhibitors or inducers.\n* Receipt of a live vaccine within 30 days of the first dose of study treatment.\n* Infection requiring parenteral antibiotics, antivirals, or antifungals within 1 week of the first dose of study treatment.\n* Evidence of HBV or HCV infection or risk of reactivation.\n* Known history of HIV (HIV 1/2 antibodies).\n* History of organ transplant, including allogeneic stem-cell transplantation.\n* Known hypersensitivity or severe reaction to any component of study drug(s) or formulation components.\n* Presence of a gastrointestinal condition that may affect drug absorption.\n* Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study.\n* Any condition that would, in the investigator's judgment, interfere with full participation in the study,pose a significant risk to the participant; or interfere with interpretation of study data",
    "miscellaneous_criteria": ""
}